4.3 Article

Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer

期刊

出版社

COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/cshperspect.a026575

关键词

-

资金

  1. European Research Council [294666_DNAMET]
  2. 7th framework program of the European Union (4DCellFate)
  3. 7th framework program of the European Union (INGENIUM)
  4. Danish Cancer Society
  5. Danish National Research Foundation (DNRF) [82]
  6. Danish Council for Strategic Research
  7. Danish Medical Research Council
  8. Novo Nordisk Foundation
  9. Lundbeck Foundation
  10. Novo Nordisk Foundation (Novo Nordisk Foundation Section for Stem Cell Biology in Human Disease)
  11. Novo Nordisk Foundation Section for Basic Stem Cell Biology [Helin group NNF] Funding Source: researchfish
  12. The Danish Cancer Society [R90-A5943] Funding Source: researchfish

向作者/读者索取更多资源

The chromatin environment is modulated by a machinery of chromatin modifiers, required for the specification and maintenance of cell fate. Many mutations in the machinery have been linked to the development and progression of cancer. In this review, we give a brief introduction to Polycomb group (PcG) proteins, their assembly into Polycomb repressive complexes (PRCs) and the normal physiological roles of these complexes with a focus on the PRC2. We review the many findings of mutations in the PRC2 coding genes, both loss-of-function and gain-of-function, associated with human cancers and discuss potential molecular mechanisms involved in the contribution of PRC2 mutations to cancer development and progression. Finally, we discuss some of the recent advances in developing and testing drugs targeting the PRC2 as well as emerging results from clinical trials using these drugs in the treatment of human cancers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据